All News

A new study suggests inhibiting ActivinA might improve the efficacy of chemotherapy in patients with B-cell acute lymphoblastic leukemia (B-ALL).

The Shield blood test developed by Guardant has been approved by the FDA as a primary screening option for colorectal cancer, providing a more convenient method of screening.

A study demonstrates the value of incorporating protein signatures in creating more advanced prediction tools for patient outcomes.

Psoriasis is not an independent risk factor for developing chronic obstructive pulmonary disease (COPD), according to a new study.

Researchers identify potential reductions in statin and antihypertensive therapy eligibility using Predicting Risk of cardiovascular disease EVENTs (PREVENT) equations.

Efforts aim to protect health sector from rising threats; chronic anxiety nearly triples dementia risk; patients report overdoses up to 20 times the prescribed dosage of compounded semaglutide.

Suicide has emerged as the leading cause of death among Asian American and Pacific Islander (AAPI) youths, a demographic that is rapidly growing in the United States.

Post–hematopoietic cell transplantation (HCT) prophylaxis using cyclophosphamide to stave off graft-vs-host disease had positive results compared with calcineurin inhibitor–based prophylaxis, regardless of whether the patient had a matched or unmatched donor.

Patricia Cioe, PhD, presented data at AIDS 2024 from a study that investigated the impact of peer support on people living with HIV who smoke, a group for whom there are higher rates of cardiac events and cancer.

Should the FDA require that new trial design proposals for perioperative regimens for resectable non–small cell lung cancer (NSCLC) include adequate within trial assessment?

The hospitalization rate for patients with pulmonary hypertension (PH) and interstitial lung disease (ILD) doubled over a 2-year period, and total health care costs more than doubled over the same period.

This systematic review focusing on the targeted therapy era found solid associations between measurable residual disease (MRD) and clinical outcomes in patients with chronic lymphocytic leukemia.

Trials of Duchenne muscular dystrophy (DMD) treatments targeting declining lung or upper limb function, which are typically limited to nonambulatory patients, could also include ambulatory patients, according to the study's findings

When the mercury outside ascends too high early in pregnancy, the risk of pediatric acute lymphoblastic leukemia may rise as well; results also show greater impacts on Latino populations.

An innovative CRISPR-Cas12f-based activator system may hold significant potential in the future of gene therapy and biological research, suggest researchers of a new study.

Despite numerous trials, breast cancer immunotherapies have had a modest clinical impact, with only 2 approved drugs, highlighting inefficiencies in the clinical trial system.

Patients with alopecia areata (AA) face significant out-of-pocket costs for treatments, despite many having limited efficacy.

A recent study showed that the Myasthenia Gravis (MG) Symptoms PRO scales viably measure core symptoms of the disease.

This week, the Center on Health Equity & Access delved into the state of equity as it relates to national spending, ovarian cancer care, health technology, insurance coverage, and postpartum depression.

The Alliance AO91902 trial investigated whether adding immunotherapy to chemotherapy would improve outcomes for patients with advanced angiosarcoma.

The authors of the new meta-analysis aimed to provide an update on the association between ankylosing spondylitis and cancer incidence.

Doug Fulling, MA, and Andrew Cournoyer of Precision AQ discussed what payers can contribute to discussions around drug pricing during clinical development.

Results from a single-center, observational, prospective study suggested that inflammatory markers could predict disease severity and treatment efficacy for patients with spinal muscular atrophy (SMA).

The ending of the 2023 film “Barbie,” where she sees a gynecologist, has increased online search interest in gynecology; yesterday marked 34 years of the Americans With Disabilities Act (ADA); Texas Attorney General Ken Paxton is suing the Biden administration over Title X, a federal contraception program that provides teens birth control without parental consent.

The FDA has approved deuruxolitinib, an oral medication developed by Sun Pharma, as the first-line treatment for adults with moderate to severe alopecia areata.

Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.

Artificial intelligence (AI) models have potential to help clinicians assess risk in patients with hepatocellular carcinoma (HCC) to inform disease management, a new study found.

The gene therapy giroctocogene fitelparvovec demonstrated superiority compared with the standard of care, routine prophylaxis, in hemophilia A treatment.

Legal and policy experts on a KFF webinar explained how the Supreme Court’s recent decision to overturn the Chevron precedent will impact legislators, agencies, and courts as they interpret and enforce policies in the health care realm.

These 48-week data from ARTISTRY-1 build on 24-week results previously presented and show enduring efficacy of bictegravir plus lenacapavir.